HeyJaredDeepa Varma
- Indexed articles, last 90 days
- 12
- Latest publication
- Aug 28, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 7, 2026
Latest articles
Atopic Dermatitis Linked to Lower Height in Children (opens the original)
Read excerpt
Children aged 5-11 years with moderate-to-severe atopic dermatitis (AD) had lower heights but higher weights and BMIs than reference percentiles, with the largest height deficit observed in boys, according to a study. “This study analysis found that moderate-to-severe AD might be associated with a reduced pediatric growth and increased BMI in children 5 to < 12 years of age, with height most affected in male children,” the authors of the study wrote. “Further studies are needed to confirm the fi
Cherry Angiomas Linked to Neurofibromatosis Type 1 (opens the original)
Read excerpt
Cherry angiomas (CAs) were common in individuals with neurofibromatosis type 1 (NF1) compared with control individuals without NF1. Biallelic NF1 inactivation in endothelial cells and telocytes supported CAs as a vascular manifestation of NF1. The results of the study “suggest that CAs represent a previously unrecognized vascular manifestation of NF1 that is associated with biallelic NF1 inactivation and frequently cooperating with G-alpha-q pathway variants,” the authors of the study wrote. By
Vitiligo Severity Assessments Vary Among HCPs (opens the original)
Read excerpt
Healthcare providers (HCPs) across the US and Europe assessed nonsegmental vitiligo (NSV) severity using multiple factors; patient quality of life (QOL) was the most important consideration. “Findings from this study highlight the need for a more consistent, patient-centered approach to the management of NSV in clinical practice,” the authors wrote. They added, “clinicians should prioritize shared decision-making by aligning treatment goals with patient expectations, including both repigmentatio
Upadacitinib Effective for Severe Alopecia Areata (opens the original)
Read excerpt
Upadacitinib, an oral selective JAK inhibitor, significantly improved scalp hair regrowth and quality of life vs placebo in adults and adolescents with severe alopecia areata (AA) in two phase 3 trials. “In these two parallel phase 3 replicate randomized clinical trials, the 24-week double-blinded period A of UP-AA1 and UP-AA2 demonstrated the superiority of both 15-mg and 30-mg upadacitinib compared with placebo in adult and adolescent patients with severe AA,” the authors of the study wrote. T
Skin Cancer Prevention Gaps Seen in Indigenous Adults (opens the original)
Read excerpt
A survey of 70 American Indian/Alaska Native (AI/AN) adults in South Dakota found a low rate of sunscreen use and gaps in skin cancer knowledge, including an underestimation of melanoma risk. “AI/AN populations carry a disproportionate yet underrecognized skin cancer burden; closing this gap requires both clinical engagement and inclusion of Indigenous perspectives in dermatologic research and training,” the authors wrote. With no cultural practices tied to skin cancer prevention, they added, “s
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.